Product Description
Mechanisms of Action: Unknown
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Vaginal
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: NEXBIOME THERAPEUTICS
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
![Map of Global Clinical Trials for BGY-1601-VT](https://pryzm-maps.s3.us-west-2.amazonaws.com/666666current_maps.png)
Countries in Clinic: France, Germany
Active Clinical Trial Count: 2
Highest Development Phases
Phase 2: Candidiasis, Vulvovaginal|Vaginal Diseases|Vaginosis, Bacterial
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
ELINA | P2 |
Not yet recruiting |
Candidiasis, Vulvovaginal|Vaginosis, Bacterial|Vaginal Diseases |
2025-12-28 |
|
BGY-1601-VT-001 | P2 |
Not yet recruiting |
Vaginosis, Bacterial |
2025-07-31 |